ARS Pharmaceuticals (SPRY) Cash from Investing Activities (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Cash from Investing Activities data on file, last reported at $27.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 4.38% year-over-year to $27.8 million; the trailing twelve-month figure through Mar 2026 stood at $55.5 million (up 180.99% YoY), and the FY2025 full-year result was $56.8 million, up 153.5% from the prior year.
• Cash from Investing Activities grew to $27.8 million in Q1 2026, from $24.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $48.6 million in Q2 2025 to a low of -$111.5 million in Q1 2023.
• A 5-year average of -$6.4 million and a median of -$22000.0 in 2022 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 204509.09% in 2023, while the deepest fall reached 531071.43% in 2023.
• Tracing SPRY's Cash from Investing Activities over 5 years: stood at -$126000.0 in 2022, then soared by 20765.87% to $26.0 million in 2023, then tumbled by 490.8% to -$101.8 million in 2024, then jumped by 123.7% to $24.1 million in 2025, then rose by 15.25% to $27.8 million in 2026.
• Business Quant data shows SPRY's Cash from Investing Activities at $27.8 million in Q1 2026, $24.1 million in Q4 2025, and -$45.0 million in Q3 2025.